Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunomedics, Inc.

http://www.immunomedics.com

Latest From Immunomedics, Inc.

Coronavirus Notebook: EU Strikes Deals For Gilead’s Veklury, Janssen’s Vaccine

Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics. 

Europe International

Finance Watch: Five More Biopharma IPOs In The US Raise $624.7m

Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.

Financing Growth

Stockwatch: Can Gilead Wave Its Wand Over Antibody-Drug Conjugates?

After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?

Platform Technologies M & A

'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout

Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.

Cancer BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • IBC Pharmaceuticals, Inc.
UsernamePublicRestriction

Register